The life sciences industry has made significant strides in digitizing operations across clinical development and commercial engagement. However, many organizations still struggle with fragmented data, manual coordination, and delayed responses, hindering real-time decision-making. Systems of Execution (SoE) offer a transformative solution by enabling real-time orchestration of tasks, detecting risks, triggering outcomes, and optimizing execution across the enterprise. Watch Everest Group experts Durga Ambati, Chunky Satija, and Nisarg Shah as they delved into the concept of SoE, exploring high-value use cases and industry considerations for successful implementation. Learn how SoE platforms can unify data across commercial, medical affairs, and patient services to deliver coordinated, stakeholder-centric engagement, and how they can act as an intelligent execution layer that bridges core systems and AI applications.

In the dynamic life sciences clinical development field, patient engagement has emerged a vital innovation and success driver. As clinical research evolves, integrating patient perspectives and active participation has become a transformative force, significantly enhancing clinical trials’ quality and relevance. Effective patient engagement throughout the clinical trial process, from study design and recruitment to data collection and result dissemination, ensures that trials are more patient-centric, efficient, and likely to yield meaningful insights. Patient engagement in clinical development is not merely a regulatory requirement but a strategic imperative. Patients who are engaged are more likely to participate in clinical trials and remain committed throughout the study, thereby reducing dropout rates and accelerating the research timeline. In this report, we assess start-ups that provide clinical trial patient engagement solutions, offering insights into capabilities, market impact, and the evolving landscape. Furthermore, from creating patient advisory boards to using patient-reported outcomes, we will explore practical strategies to incorporate patient engagement into clinical development. We will also examine case studies and best practices that illustrate patient-centric approaches’ tangible benefits. Scope Industry: life sciences Geography: global Contents In this report, we Examine the drivers and barriers to patient engagement solution adoption in clinical trials Introduce a framework to evaluate high-potential start-ups in the patient engagement market Highlight the trailblazers in patient engagement, including their assessment, leaderboard, and profiles Membership(s) Clinical Development Technology Sourcing and Vendor Management

Patient recruitment is a complex and dynamic part of clinical trial management, requiring proactive strategies, collaborations, and innovation to overcome challenges and achieve enrollment targets. Patient recruitment is vital for clinical trials, yet it presents challenges that impact study timelines, costs, and overall success. By adopting patient-centric approaches, using technology, and fostering collaborations across stakeholders, organizations can enhance recruitment efficiencies and accelerate study timelines, ultimately introducing new treatments to market faster for patients’ benefit worldwide. Patient recruitment in clinical trials will evolve due to technology advances, changing regulatory landscapes, and dynamic patient expectations. Outsourcing patient recruitment to specialized firms offers enterprises and Contract Research Organizations (CROs) opportunities to use expertise, scalability, and flexibility in navigating enrollment complexities. In this report, we examine the patient recruitment landscape, including the challenges that sponsors face. The report also assesses the current state of the supplier ecosystem and explores technology’s role in solving major challenges in patient recruitment. Scope Industry: life sciences Geography: global Services: life sciences BPS, life sciences ITS, and clinical development technology Contents In this report, we: Examine the patient recruitment landscape, including the challenges that sponsors face The report also assesses the current state of the supplier ecosystem and explores technology’s role in solving major challenges in patient recruitment Membership(s) Life Sciences Business Process Sourcing and Vendor Management

Decentralized clinical trials (DCTs) were a boon during the pandemic. Pharmaceutical enterprises capitalized on the opportunity to conduct remote and virtual trials during a time when isolation was critical. However, in 2023, pharmaceutical enterprises are turning their focus to address new challenges such as scale, data security, and site engagement. In this webinar, our experts presented insights on the trends pharmaceutical enterprises should expect this year, along with data from our 2023 DCT Platforms PEAK Matrix® assessment to shed light on both the demand and supply side of this market. Our speakers discussed: How is the DCT technology market evolving and what does adoption look like across therapy areas and geographies? What sourcing criteria should pharmaceutical enterprises consider for evaluating their DCT needs? What are the supply landscape characteristics and their value propositions?

Decentralized Clinical Trials (DCTs), in which clinical trial data is collected through sensors or remote monitoring devices, can deliver many benefits to pharmaceutical companies, including cost savings, better patient recruitment and retention, and improved data quality. DCTs rose to popularity during the pandemic as people around the world were advised to stay indoors. The top reason for shifting to this model is DCTs’ patient-centered focus, which makes it easier for more people from a broader geographic spread to participate in trials without the need to visit a site. Enterprises are now shifting away from a site-anchored approach to hybrid or completely decentralized trials and looking to convert their piecemeal deployments into a comprehensive adoption strategy. This playbook looks at 50+ DCT case studies across different therapy areas and informs enterprises about the trends, benefits, and challenges in DCT adoption to help them design a strategy for seamless DCT adoption. Scope Industry: life sciences Geography: global Contents This report studies: Everest Group’s view of an end-to-end unified DCT platform Current trends in DCT adoption Everest Group’s framework for DCT adoption DCT use-case compendium Membership (s) Life Sciences Information Technology Sourcing and Vendor Management

Today’s clinical trials are faced with challenges such as high patient dropout rates, rising cost of drug development, significant failure rates, and an increase in trial duration. While the drug pipeline has grown over the last few years, the efficiencies in clinical trials have not followed a similar trend. Rather, it would be surprising to find that the clinical trials are still as inefficient as they were a decade ago, despite the introduction of technologies such as analytics. There is, therefore, a need to transform clinical trials for the better, by bringing in technological interventions to improve efficiency, speed, costs, and also make the trials more patient centric. In order to transform their clinical trials, enterprises will need to prioritize their investments in these technologies, develop a strategy for external collaboration, and adopt a platform strategy to unify the clinical trial applications landscape. Scope of the analysis Geography: Global Industry: Life sciences Sources leveraged Expert analyst inputs Previous Everest Group research Secondary data sources that are publicly available Contents This report presents the current state of clinical trials, the factors responsible for the change in the trial ecosystem, six interventions that will change the face of clinical trials for the better, and the business imperatives for industry stakeholders to reach the desired state faster. This report is structured across three key sections, each containing insights into the clinical trials ecosystem: Current state of clinical trials Future of clinical trials Drivers for change in the clinical trial landscape Key interventions that will change the trial landscape Patient-centric virtual trials Digital biomarkers and digital endpoints Using innovation to access untapped markets In silico clinical trials Adaptive trials Blockchain for clinical trial data management Business imperatives Developing a collaborative strategy Adopting a unified platform strategy for clinical trial management Prioritizing investments in promising technologies Membership(s) Life Sciences IT Services (ITS)